Rigel Pharmaceuticals, Inc.
Kinase inhibitors and methods for making and using

Last updated:

Abstract:

Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors according to Formula 1, and compositions comprising such inhibitors. ##STR00001## Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

Status:
Grant
Type:

Utility

Filling date:

12 Feb 2020

Issue date:

13 Jul 2021